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there appearance forces the clinician to consider the possibility
of rhombencephalitis.4 Regarding immunosuppressive treatment
of the patients in  the series by Horta-Baas et al., five cases had
previously received MMF  but none rituximab.1 Four cases of
meningitis/encephalitis due to L. monocytogenes associated to rit-
uximab have been published, all of them in adult patients with
an underlying hematologic malignant process.5,6 Infection with L.
monocytogenes in pSLE is  rare, found in  the literature only in  a
5  year old patient with type IV lupus nephritis, neurologic alter-
ations and antiphospholipid syndrome who developed bacteremia
due to L. monocytogenes,  treated and solved with ampicillin.7 One
aspect that is also interesting in  our  patient is the subsequent
appearance of other severe neurologic infections after the admin-
istration of rituximab.
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Genetic Characteristics of Rheumatic Patients
Developing Inflammatory Skin Lesions Induced
by Biologic Therapy
Características genéticas de pacientes reumatológicos que
desarrollan lesiones cutáneas inflamatorias inducidas
por fármacos biológicos
Dear Editor,
The appearance of inflammatory skin lesions (ISL), induced by
biological drugs, mainly cutaneous psoriasis, has been extensively
described.1–3 The hypothesis is  that in patients with genetic suscep-
tibility present an activation of alternative inflammatory pathways
such as interferon-  1.2, but this has not been demonstrated and
no genetic studies in  these patients exist.
We  conducted a prospective observational study analyzing
genetic data from patients of the Rheumatology Department of the
Hospital del Mar  (Barcelona) who developed de novo ISL due to
biological therapy between January 2008 and December 2012.
The demographic and clinical variables evaluated were: age, sex,
diagnosis of ISL, rheumatic disease and duration (in years), biologic
drug employed and time from onset to the start of the drug (weeks).
Genetic variables were the presence of HLA-B27, HLA-DR1, HLA-
DR4 and HLA-DR7 alleles (detected by standard PCR), HLA-CW6
(Sanger sequencing using the indirect marker rs4406273) and the
deletion of two genes late cornified envelope (LCE), LCE3C LCE3B-del
(with a multiplex PCR experiment4). Fifteen patients who devel-
oped ISL (prevalence 2.5%) were included. They had a mean age
of  43.9 ± 12.4 years and 73.3% were female. The diagnoses of
ISL were: seven skin psoriasis (five palmoplantar pustulosis, one
with psoriasis vulgaris and one with guttata), three alopecia areata,
two cutaneous lupus, one eczema, one suppurative hidradenitis
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and one with erythema multiforme. Rheumatological diagnoses
were: three rheumatoid arthritis, ankylosing spondylitis 6, four
non-radiological axial spondyloarthritis and two psoriatic arthritis,
mean disease duration of 13.1 ± 7.4 years. Biologic drugs were eight
cases using adalimumab, etanercept in four, infliximab in  two and
abatacept in  one, with a mean time  of onset of 57.1 ±  62.1 weeks.
Genetically, seven patients had HLA-B27, four were HLA-CW6
positive (26%), only one with psoriasis, one positive HLA-DR1,
another HLA-DR4 and six HLA-DR7 positive patients (40%), three
with psoriasis. In four patients (26.7%) two  LCE3C-LCE3B deleted
alleles were detected and 11 (73.3%) had one deleted allele
(Table 1). LCE3C LCE3B allele frequency was 63.6%.
The low proportion of patients with the presence of HLA-CW6
and HLA-DR7 alleles (especially in  cases of psoriasis) stands out,
lower than that found in  populations of cutaneous psoriasis,5–7
which could be due to the predominant type of psoriasis, palmo-
plantar pustulosis, since the average age of patients was older than
40 years (HLA-CW6 and HLA-DR7 alone have been associated with
type I psoriasis, with an onset before 40 years of age, and with the
vulgaris and guttate subtypes5).
In  our series, the presence of the deletion of the two LCE genes
(allele frequency of 63.6%) was consistent with the frequently seen
in population samples with inflammatory diseases (62%–70%) but
higher than that  reported in  control populations (55%–60%).4,8–10
But what stands out is that all patients with ISL had at least
one copy of the LCE3C LCE3B deleted alleles (absence of non-
deleted homozygous individuals). In the general population, the
frequency of non-deleted homozygotes is  around 18%4,9,10 and dis-
ruption of the skin barrier occurs in  relation to the number of  copies
of LCE3C LCE3B, being undetectable in  carriers of the homozygous
deletion4 and reduced in  heterozygotes.
This observational study of a series of cases of ISL induced by
biological drugs and is the first to  include genetic data, although
further studies are  needed with larger numbers of patients and a
control group to better study this process and help establish if there
a pattern of genetic susceptibility as in  the case of LCE3C LCE3B
deletions.
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Table  1

















Skin psoriasis 7 4  1 1 0 3 3 4
Alopecia areata 3 1  1 0 0 1 1 2
Cutaneous lupus 2 0  1 0 0 1 0  2
Eczema 1 1  0 0 0 1 0  1
Hydradenitis 1 1  0 0 0 0 0  1
Erythema multiforme 1 0  1 0 1 0 0  1
Total 15  7  4 1 1 6 4 11
LCE 3B-3C-LCE del, deletion of the late cornified envelope; ISL, induced skin lesions; N.p., number of patients; +, positive; D+, deleted; D−, non-deleted.
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Usefulness of Ultrasound in  Jaccoud’s
Arthropathy. A Case Report
La ecografía en la artropatía de Jaccoud. A propósito de un caso
To the Editor,
Joint involvement is one of the initial manifestations in most
patients with systemic lupus erythematosus (SLE); ranging from
joint pain to severe deforming arthritis.1 Within the deforming
types, non erosive forms, such as Rhupus and others such as
Jaccoud’s arthropathy (JA),2 non-erosive in principle, occurs in
10%–35% of patients with SLE.3
Ultrasound has proven superior to  clinical examination in
detecting joint and tendon inflammatory activity in patients with
SLE.2 We  report a  patient with SLE and JA in which this technique
was useful in the assessment of disease.
The patient is  a 40-year-old woman from Honduras diagnosed
with SLE 4 years prior and, has presented during her evolution,
joint pain and arthritis of small proximal joints of the hands, wrists,
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knees and elbows; scarring alopecia; Raynaud’s phenomenon and
subacute cutaneous lupus erythematosus lesions. She had positive
antinuclear antibodies (1/1280), anti-dsDNA, anti-Sm, anti-RNP
and anti-CCP (high titers); anemia of chronic diseases and com-
plement consumption. From the onset of the disease she  has been
treated with hydroxychloroquine, methotrexate and prednisone.
Fig. 1. Left hand of the patient with Jaccoud’s arthropathy where ulnar deviation of
the 5th finger and swan neck deformity of fingers 2–5 is  appreciated.
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